Kintara Therapeutics, Inc.

12707 High Bluff Drive, Suite 200

San Diego, CA 92130

 

November 2, 2020

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E. 

Washington, D.C.  20549

 

Re:

Kintara Therapeutics, Inc. (the “Company”)

Registration Statement on Form S-3 (File No. 333-249675)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:15 p.m., Eastern Time, on November 4, 2020, or as soon as practicable thereafter.

 

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.

[Signature page follows.]


 

U.S. Securities and Exchange Commission

November 2, 2020

Page 2

 

 

 

Very truly yours,

 

KINTARA THERAPEUTICS, INC.

 

 

 

 

 

 

By:

/s/ Scott Praill

 

 

Name:

Scott Praill

 

 

Title:

Chief Financial Officer

 

-2-